DBV Technologies S.A. Stock: price and insider trades · United States

DBV Technologies S.A. is a specialty biopharmaceutical company listed on the NASDAQ market in the United States, while remaining legally domiciled in France. For French-speaking investors, the company fits the profile of a high-research-intensity biotech: substantial upside if regulatory and commercial milestones are achieved, but also meaningful clinical, financing, and execution risk. DBV was incorporated on March 29, 2002 as a French SAS and later converted into a société anonyme in 2003. Its principal executive offices are in Châtillon, France. Although the shares trade in the United States, the issuer itself is a French company with SEC reporting obligations.

DBV’s business is built around its proprietary VIASKIN platform, an epicutaneous immunotherapy technology designed to deliver allergens through the skin via a patch. The company’s lead asset is the Viaskin Peanut Patch, which is being developed for peanut allergy, one of the most common and clinically significant food allergies. DBV’s development strategy currently focuses on two pediatric populations: children aged 4 to 7 years, for which the company has been working toward a U.S. Biologics License Application submission in 2026, and toddlers aged 1 to 3 years, for which it has discussed an accelerated regulatory path with the FDA. DBV does not yet generate product revenue, so its valuation remains largely tied to clinical and regulatory progress.